Trials / Active Not Recruiting
Active Not RecruitingNCT06610526
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 731 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.
Detailed description
This is an interventional, multicentre, Phase IV, single-arm, open-label study to investigate the efficacy and safety of dapagliflozin to prevent the progression of chronic kidney disease in Chinese adult patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | Dapagliflozin by oral administration |
Timeline
- Start date
- 2024-08-23
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
- First posted
- 2024-09-24
- Last updated
- 2026-01-30
Locations
34 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06610526. Inclusion in this directory is not an endorsement.